Global Impact Fund.

Impact thesis:
‍Boralex develops solar and wind projects which helps contribute to the overall energy production mix and as they grow, help promote the shift from a fossil fuel reliant energy system to renewable power.

Case study:

Boralex has partnered with the Innu Nation on the Apuiat wind project in the Côte-Nord region of Quebec to create a 200-MW wind farm. 


The wind farm will be located on the public land of the traditional territory (Nitassinan) of the Uashat mak Mani-utenam First Nation and is expected to:

• Create a long-term clean energy source
• Generate sustainable economic and social benefits for Innu communities
• Open up nearly 300 jobs to the Innu community during the construction phase, along with approximately 10 permanent jobs for the wind farm's operations. In addition to getting a special recruiter, members of the Innu community will be trained in wind turbine maintenance through a customized program.

The Innu communities and Boralex each hold 50% of the votes on the Apuiat Wind Farm's Board of Directors.

Impact thesis:
‍BRI is focused on becoming the Financial Inclusion leader and we believe they are and will continue to do this by providing micro and ultra-micro loans primarily to small businesses which we believe enables:

• Empowerment of underprivileged community groups so that they can become independent entrepreneurs
• Providing more complete financial products and services
• Expansion and ease of access to financial services

In addition, BRI has a subsidiary dedicated to providing loans to underprivileged women through their ultra-micro ecosystem.  

Case study:
‍The need to conduct financial transactions digitally must be deeply embedded within customers’ daily activities to ensure its sustainability. Three pioneers of financial inclusion: Bank Rakyat Indonesia, Pegadaian (Indonesia’s largest pawn lender), and PNM (Indonesia’s largest group lender that focuses on empowering women) have joined hands to create an ultra-micro ecosystem. Together, they aspire to become one of the world’s largest micro-finance institutions, bringing more than 30 million customers out of poverty over the next four years.

Impact thesis:
‍ATS Corp is a leader in automation solutions with customers spread across hundreds of regulated end-markets including electric vehicle manufactures, life sciences, food and beverage companies, renewable energy, and consumer products.

Case study:
‍As an automotive manufacturer transitions to electric vehicle (EV) production, the stakes are high, especially in the realm of battery assembly. The rapid evolution of battery technology, coupled with aggressive production targets and the need for efficient use of existing facilities, poses significant challenges. These challenges can add millions of dollars in costs and delay to critical EV projects.

Partnering with ATS, a manufacturer leveraged ATS's global reach, scalability, and project management expertise to help scale its battery manufacturing. Together, ATS worked with the manufacturer to design and implement an innovative automotive assembly system. Applying their extensive knowledge of battery cell types, the team developed a modular assembly system based on ATS’s SuperTrak CONVEYANCE™ Platform.

With this modular platform, the manufacturer gained a 50% improvement in floor efficiency, maintaining their project schedule, and keeping to a budget.

Impact thesis:
‍Insulet brought the first truly wearable, automated, insulin delivery system controlled by a phone to market – the Omnipod.

We believe that the Omnipod System increases the standard of care for patients by:

• Reducing the number of days that you need to inject (1 pod replaces ~14 injections)
• Tracking insulin levels while increasing the level of precision in terms of accurate insulin injection
• Reducing mental burden associated with living with insulin-dependent diabetes (approximately 300 decisions are made per day to manage glucose levels)

‍

Case study:
‍Insulet began as a father’s vision to find a better alternative to  his young son’s limited options for insulin delivery. This led to Insulet’s groundbreaking innovation of making insulin delivery wearable with Pod therapy.  

Today, the company offers the revolutionary Omnipod 5 Automated Insulin Delivery System - the first tubeless, wearable automated insulin delivery (AID) system in the U.S., with significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years with type 1 diabetes over 12 months of use. This trial extension data was presented at the American Diabetes Association 82nd Scientific Sessions in New Orleans, Louisiana.

Several publications have found that compared to Multiple Daily Injection (MDI) therapy, the use of the Omnipod System by individuals with both type 1 and type 2 diabetes is associated with good glycemic control and reduced frequency and severity of hypoglycemic episodes. These results are consistent with published literature of other continuous subcutaneous insulin infusion devices.

"One of our biggest goals in the development of Omnipod 5 was to ease the burden that type 1 diabetes places on families and caregivers of this vulnerable age group,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “With these preschool extension trial results, we have demonstrated improved glycemic results over the long term for very young children managing diabetes. I’m incredibly proud of this remarkable achievement and know that Omnipod 5 will have a big impact on these families."